Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15618MR)

This product GTTS-WQ15618MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF13C gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_052945.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 115650
UniProt ID Q96RJ3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15618MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1753MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ14046MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ13450MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ8503MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ9757MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ1289MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ4623MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ14298MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW